Bioanalysis, biomarker assay development, validation and sample analysis.
Drug development and manufacturing for biologics and small molecules, with integrated services from preclinical, clinical to commercial.
Best-in-class drug discovery products and services to identify and develop life-changing therapies.
Global insourcing solutions delivering on-site scientific and laboratory services.
Delivering safety, efficacy, biomarker, and pathology services, through a global network of CAP accredited laboratories.
Solutions from discovery through commercialisation.
With facilities in Europe, North America and Asia, we support clients in the pharma, diagnostics, food, agriculture, biotechnological and research markets.
Comprehensive BioPharma Product Testing: a leader in testing biologics, CGT, nucleic acid therapies, and small molecules from early developm…
With over 40 years of expertise and capabilities, Eurofins Medical Device Services offers comprehensive solutions across the entire medical…
Xin Yi, 易芯,Marketing Supervisor, Eurofins BioPharma Product Testing Shanghai
Eurofins BioPharma Product Testing is delighted to announce its first laboratory facility opening in Shanghai in March 2023, (Eurofins BPT Shanghai).
The Eurofins BPT Shanghai site has been under construction since 2021 and covers an area of approximately 2000 m². The laboratory construction was completed with the support of Eurofins’ European and US laboratories, using a globally harmonised LIMS, which meets the requirements of GMP regulations in China, the US and Europe. As the 40th GMP laboratory in the global Eurofins laboratory network, the Eurofins BPT Shanghai facility can provide safety testing services under GMP conditions for drugs and medical devices. Eurofins BPT Shanghai laboratory testing capabilities include:
Eurofins BPT Shanghai has well-trained experienced scientists who are experts on regulations spanning China, US, Europe and Japan. The team can also develop quick and stable testing methods based on global experience and client requirements. This ensures each product’s quality and safety and enables Chinese pharma customers to accelerate the process of product commercialisation overseas.